Skip to content

VRTX · VERTEX PHARMACEUTICALS INC / MA

29 filings

10-K

VRTX 10-K Annual Reports

VERTEX PHARMACEUTICALS INC / MA - 29 annual reports

Filing record · 2016–202610-K1110-Q328-K100

2025
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2025
Vertex Pharmaceuticals' FY2025 10-K shows a company at an inflection point: total revenues rose 9% to $12.0 billion, operating income swung to $4.2 billion from a $232.9 million loss in 2024 (which had been depressed by a $4.4 billion non-deductible Alpine acquisition charge), and net income reached $3.95 billion, or $15.32 diluted EPS. The core CF franchise remains the economic engine, with TRIKAFTA/KAFTRIO generating $10.3 billion, roughly 86% of product revenue, while newer launches are gaining traction: ALYFTREK contributed $837.8 million, CASGEVY $115.8 million and JOURNAVX $59.6 million. Operating cash flow recovered to $3.6 billion, and cash plus marketable securities grew to $12.3 billion, supporting a $4.0 billion buyback authorization with $3.4 billion still available. The investment case increasingly depends on the pipeline rather than CF. Management expects to complete the povetacicept BLA for IgA nephropathy in the first half of 2026 using a priority review voucher, with interim data pending, and plans to report AMKD interim data in late 2026 or early 2027. Management also expects SG&A and cost of sales to rise in 2026 as JOURNAVX, povetacicept and CASGEVY scale. Key risks include ongoing pricing pressure (the IRA, state PDABs and the proposed GUARD model), the Royalty Pharma arbitration over the ALYFTREK royalty rate (Vertex accounts for 4%, RP asserts roughly 8%), the $379 million impairment of the VX-264 T1D asset, the temporary pause in zimislecel dosing pending a manufacturing analysis, and the August 2025 setback for suzetrigine in broad peripheral neuropathic pain. At the balance-sheet level the company is conservative: it has no drawn debt on its $500 million revolver, an effective tax rate of 14.9%, and a clean audit opinion from Ernst & Young with an unqualified internal-control opinion. Concentration remains high, since substantially all product revenue comes from CF medicines and McKesson accounts for 22% of gross product revenue.
Feb 13, 2026
2024
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2024
Vertex Pharmaceuticals (VRTX) closed 2024 with net product revenues of $11.0 billion, up 12% from $9.9 billion in 2023, driven by TRIKAFTA/KAFTRIO demand, younger-age expansions, and higher U.S. net realized pricing. However, reported results swung to a net loss of $535.6 million (-$2.08 per diluted share), versus net income of $3.6 billion in 2023. The swing was driven by a $4.4 billion non-deductible acquired in-process R&D charge from the May 2024 acquisition of Alpine Immune Sciences (for approximately $5.0 billion in cash) and its lead asset povetacicept, which was expensed as an asset acquisition. Excluding this charge, the underlying business remained highly profitable, though operating expenses rose sharply with R&D up 15% to $3.6 billion and SG&A up 29% to $1.5 billion. Balance sheet liquidity fell as cash, equivalents and marketable securities declined to $11.2 billion from $13.7 billion, reflecting the Alpine purchase and $1.2 billion of share repurchases. Operating cash flow was negative $492.6 million for 2024 (versus $3.5 billion in 2023), largely due to the Alpine payment. Management expects product revenues to grow in 2025 from ALYFTREK (approved December 2024, once-daily triple combination), CASGEVY infusions, and the January 2025 launch of JOURNAVX, a non-opioid acute pain drug. The company has no debt drawn under its $500 million revolver and states cash flows should fund operations for at least twelve months. Key risks remain concentrated: substantially all product revenue comes from CF medicines, pricing pressure from the IRA and state PDABs, a December 2024 FDA boxed warning on liver injury for TRIKAFTA and ALYFTREK, and a pending patent trial against Lupin on KALYDECO granules scheduled for September 2025. The pipeline has several 2025 catalysts, including VX-522 mRNA data for CF, the AMPLITUDE and RAINIER interim analyses for potential accelerated approvals in AMKD and IgAN, and zimislecel Phase 3 enrollment in type 1 diabetes.
Feb 13, 2025
2023
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2023
Vertex Pharmaceuticals' FY2023 10-K shows a company whose financial profile is dominated by its cystic fibrosis franchise. Net product revenues rose 11% to $9.87 billion, driven by strong ex-U.S. uptake and label expansions of TRIKAFTA/KAFTRIO, with TRIKAFTA/KAFTRIO alone generating $8.94 billion (up 16%). Income from operations fell 11% to $3.83 billion because operating expenses rose 31% to $6.04 billion, reflecting higher R&D, $527 million of acquired in-process R&D, and pre-launch SG&A. Net income grew 9% to $3.62 billion, or $13.89 per diluted share, helped by a $548 million swing to other non-operating income driven mainly by interest income of $615 million. The effective tax rate fell to 17.4% from 21.5%, though cash taxes paid rose sharply to $1.68 billion. Operating cash flow declined to $3.54 billion from $4.13 billion, and total cash and marketable securities reached $13.7 billion. The filing's key forward-looking catalysts are the planned mid-2024 global filings for the once-daily triple combination vanzacaftor/tezacaftor/deutivacaftor and the planned mid-2024 NDA for the non-opioid pain candidate VX-548, plus the CASGEVY launch for sickle cell disease and beta thalassemia, which is expected to be a foundational but early-revenue year. Risks include heavy concentration in CF revenue, the Inflation Reduction Act and state drug-pricing pressure, the pause of the VX-880 type 1 diabetes trial after two patient deaths, and pending patent litigation over KALYDECO generics, with several settlements already reached. For investors, the central question is whether the CF franchise can keep compounding while the company funds a large, costly pipeline and multiple first-time launches. The company has ample liquidity to self-fund these efforts and continued share repurchases under a $3.0 billion program, with $2.6 billion remaining.
Feb 15, 2024
2022
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2022
Vertex Pharmaceuticals' FY2022 10-K shows a company whose growth is almost entirely driven by cystic fibrosis (CF). Net product revenues rose 18% to $8.93 billion, led by TRIKAFTA/KAFTRIO, which generated $7.69 billion (up 35%). Operating income more than doubled from a year earlier to $4.31 billion, though that comparison is flattered by the $900 million CRISPR upfront payment booked in 2021. Net income reached $3.32 billion, or $12.82 per diluted share, up from $9.01. Operating cash flow was $4.13 billion, and cash and marketable securities grew to $10.8 billion. Investors should note that the four CF medicines still account for virtually all product revenue, and that the older CF products (ORKAMBI, SYMDEKO/SYMKEVI, KALYDECO) are declining as patients switch to TRIKAFTA. The pipeline is the main source of optionality. Key programs include exa-cel (CRISPR-based gene editing for sickle cell disease and beta thalassemia, with a BLA in rolling submission), VX-548 (a non-opioid NaV1.8 pain candidate in Phase 3), inaxaplin (APOL1-mediated kidney disease, Phase 2/3), and VX-880 (stem-cell-derived islet cells for type 1 diabetes). The next-generation triple combination vanzacaftor/tezacaftor/deutivacaftor is in Phase 3, with data expected by the end of 2023. Management plans significant increases in R&D and SG&A spending in 2023 to prepare for these launches, which will pressure near-term margins. Balance-sheet strength supports this, and the board approved a new $3.0 billion share repurchase program in February 2023. The risk profile is concentrated. Substantially all revenue depends on CF, and a meaningful portion depends on the U.S. Inflation Reduction Act's Medicare drug price negotiation, along with ex-U.S. reimbursement timing. Customer concentration is high: McKesson accounted for 25% of gross product revenue. Patent litigation over KALYDECO generics is set for trial in 2024. A large uncertain tax liability rose sharply in 2022, and the effective tax rate increased to 21.5% from 14.2%. Pipeline setbacks, including the discontinuation of VX-814 in 2020 and the hold on the U.S. IND for VX-264, remain material execution risks.
Feb 10, 2023
2021
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2021
Vertex Pharmaceuticals' FY2021 10-K shows a company whose cystic fibrosis (CF) franchise is generating strong growth, led by TRIKAFTA/KAFTRIO, while it invests heavily to diversify into other serious diseases. Total revenues rose 22% to $7.57 billion, with net product revenues of $7.57 billion, driven by TRIKAFTA/KAFTRIO sales of $5.70 billion (up 47%) and ex-U.S. product revenues up 66% to $2.29 billion following KAFTRIO's European launch. Net income fell 14% to $2.34 billion (diluted EPS $9.01, versus $10.29 in 2020), largely because of a $900 million upfront payment to CRISPR Therapeutics for the amended CTX001 (sickle cell and beta thalassemia gene-editing) collaboration, which was expensed in R&D. Excluding that charge, operating profitability improved meaningfully. The balance sheet remains very strong, with cash, cash equivalents and marketable securities of $7.5 billion, working capital of $7.4 billion, and no borrowings under its $2.5 billion revolving credit facilities. Vertex repurchased about $1.4 billion of stock in 2021 under its $1.5 billion authorization, leaving roughly $0.5 billion remaining. Operating cash flow was $2.6 billion, reduced by the CRISPR payment. For investors, the key issues are concentration risk, since substantially all revenue depends on CF medicines and TRIKAFTA/KAFTRIO in particular, and the execution risk of a pipeline that includes Phase 3 CTX001 programs, VX-880 for type 1 diabetes, VX-147 for APOL1-mediated kidney disease, and VX-548 for pain. Patent litigation over KALYDECO generics (Sun and Lupin, with trial set for October 2023) and the 2022 tax change that requires amortization of R&D expenses are additional factors to monitor.
Feb 9, 2022
2020
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2020
Vertex Pharmaceuticals' FY2020 10-K shows a company that has transitioned into a highly profitable, cash-generating business on the back of its cystic fibrosis (CF) franchise. Total revenues rose 49% to $6.21 billion, driven by product revenues of $6.20 billion, with TRIKAFTA/KAFTRIO alone contributing $3.86 billion (up from $420 million in 2019). Income from operations more than doubled to $2.86 billion, and net income attributable to Vertex reached $2.71 billion, or $10.29 per diluted share, versus $4.51 in 2019. Results were also helped by $312 million of gains on strategic equity investments, and 2020 included a 13% effective tax rate aided by a one-time $209 million intellectual property transfer to the U.K. Operating cash flow was $3.25 billion. The key investor consideration is concentration risk. Substantially all revenue and the most advanced clinical assets relate to CF, and the filing explicitly ties future growth to TRIKAFTA uptake in ex-U.S. markets, reimbursement progress, and label expansion into younger children (an sNDA for ages 6 to 11 was accepted with Priority Review in January 2021). Meanwhile, Vertex is spending heavily on diversification: R&D expense was $1.83 billion, with pipeline programs in alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, pain, and cell and genetic therapies (CTX001 for sickle cell disease and beta thalassemia, and type 1 diabetes). Several of these programs are early, and the company discontinued VX-814 in October 2020 on safety grounds. Balance-sheet strength is a clear positive. Cash, equivalents and marketable securities reached $6.66 billion, working capital was $6.3 billion, the company has $2.5 billion of undrawn revolving credit, and it repurchased $539 million of stock in 2020 with $425 million remaining under its authorization. Management expects product cash flows and existing cash to fund operations for at least twelve months. Investors should watch the pace of TRIKAFTA's ex-U.S. reimbursement, the outcome of the pediatric filing, the rising cash tax burden as NOLs are used up, and the volatility introduced by strategic equity holdings.
Feb 11, 2021
2019
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2019
Vertex Pharmaceuticals' FY2019 10-K shows a company in a strong commercial and financial position, driven almost entirely by cystic fibrosis (CF) medicines. Total revenues rose 37% to $4.16 billion, with net product revenues of $4.16 billion, up from $3.04 billion. Growth came from SYMDEKO/SYMKEVI ($1.42 billion), ORKAMBI ($1.33 billion), KALYDECO ($991 million), and the first partial year of TRIKAFTA ($420 million, FDA-approved in October 2019). Income from operations nearly doubled to $1.20 billion, and net income attributable to Vertex was $1.18 billion, or $4.51 per diluted share. That is below 2018's $8.09, which was inflated by a one-time $1.56 billion tax benefit from releasing a valuation allowance. Operating cash flow was $1.57 billion, and cash plus marketable securities ended the year at $3.8 billion. The filing also highlights heavy investment in the pipeline. Vertex spent about $2.4 billion on R&D and SG&A and completed two major 2019 acquisitions: Exonics (DMD/DM1, about $245 million upfront plus milestones) and Semma (type 1 diabetes, about $950 million cash). Collaborative license and acquisition expenses were $318 million, which weighed on R&D. Investors should note that the company remains highly concentrated in CF, with the vast majority of revenue from CF products. Its ex-U.S. reimbursement challenges (for example, ORKAMBI's four-year path to reimbursement in England) and the mix shift from SYMDEKO to TRIKAFTA are key watch items. Strategic equity investments, mainly in CRISPR, also add earnings volatility, with a $197.6 million gain in 2019. Management is also transitioning. Jeffrey Leiden moves to Executive Chair and Reshma Kewalramani becomes CEO on April 1, 2020. The filing reports no material legal proceedings, an effective internal control assessment with an unqualified auditor opinion from Ernst & Young, and a $500 million 2019 share repurchase program, with $464 million remaining.
Feb 13, 2020
2018
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2018
Vertex Pharmaceuticals' FY2018 10-K shows a company whose financial results are now driven almost entirely by its cystic fibrosis (CF) franchise. Total revenues rose 22% to $3.05 billion, with CF net product revenues of $3.04 billion (up 40%), led by the U.S. launch of SYMDEKO/SYMKEVI ($769 million in its first year) and continued growth in KALYDECO ($1.01 billion). ORKAMBI declined 4% to $1.26 billion as patients switched to SYMDEKO. Net income attributable to Vertex was $2.10 billion, or $8.09 per diluted share, but this figure is inflated by a one-time, non-cash $1.56 billion income tax benefit from releasing most of the valuation allowance on net operating losses. Operating income was a more representative $635 million. Management expects future tax provisions to become significant as those NOLs are used. The main investment thesis rests on the triple combination regimens. Phase 3 data for VX-659 showed statistically significant improvements in lung function (14.0 and 10.0 percentage-point ppFEV1 gains), and data for VX-445 were expected in Q1 2019 before Vertex picks the better regimen for an NDA by mid-2019. Management says these therapies could address about 90% of CF patients, but also notes that some revenue from them will likely cannibalize existing products. Outside CF, the pipeline includes VX-150 for pain (Phase 2b), CTX001 gene editing for sickle cell disease and beta-thalassemia (with CRISPR), and an AAT deficiency candidate in Phase 1. Business development spending was significant, including $111.6 million in 2018 research expenses tied to collaborations and $65 million paid for a DNA-PK license. Risks to note include revenue concentration in CF, limited reimbursement for ORKAMBI in the UK and France, and a $354.4 million early access sales accrual in France that could be partly refunded depending on the final price. Cash, cash equivalents and marketable securities reached $3.2 billion, with no debt outstanding under a $500 million revolver. The company also repurchased $350 million of stock in 2018.
Feb 13, 2019
2017
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2017
Vertex Pharmaceuticals' 2017 10-K shows a company that has reached a turning point: it reported its first annual GAAP profit since 2011, with net income attributable to Vertex of $263.5 million (diluted EPS $1.04) on total revenues of $2.49 billion, up 46% from $1.70 billion in 2016. The result was helped by $230.0 million of one-time collaborative revenue from the Merck KGaA deal and a $107.3 million income tax benefit tied to the impairment of Parion's ENaC platform. Net product revenues rose 29% to $2.17 billion, driven by ORKAMBI ($1.32 billion) and KALYDECO ($844.6 million). Both figures were concentrated in cystic fibrosis (CF) medicines, which account for substantially all product revenue. Cash, cash equivalents and marketable securities rose to $2.09 billion, and working capital reached $1.84 billion. The filing's key investor issues are pipeline and execution risk. Management plans to start Phase 3 trials for triple-combination regimens built on next-generation correctors VX-659 and VX-445 in 2018, and SYMDEKO was approved by the FDA in February 2018. Several risks are significant. ORKAMBI ex-U.S. reimbursement remains difficult, with ex-U.S. revenue only 13% of ORKAMBI sales in 2017. About $232.4 million collected in France is held as customer deposits pending a price decision, and it is expected to be partly repaid. In September 2017 a Phase 2 VX-371 trial failed its primary endpoint, which forced a $255.3 million impairment and the deconsolidation of Parion. The company also carries about $3.6 billion of U.S. federal NOLs and a valuation allowance on most deferred tax assets, which could produce a large future tax benefit if reversed. On the balance sheet, a $500 million credit facility was repaid in February 2017 and is undrawn, a $500 million share repurchase program was authorized in January 2018, and management expects cash flows to cover operations for at least twelve months. Vertex reports no material legal proceedings, though the risk factors describe substantial exposure to product liability, pricing pressure and healthcare fraud enforcement. The primary takeaway for investors is that profitability is real but partly one-time, and future results depend on triple-combination success and on ex-U.S. reimbursement for ORKAMBI and SYMDEKO.
Feb 15, 2018
2016
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2016
Vertex Pharmaceuticals' FY2016 10-K shows a company in commercial transition, with net product revenues rising 68% to $1.68 billion, driven by ORKAMBI (launched mid-2015), which generated $979.6 million, up from $350.7 million. KALYDECO grew to $703.4 million. Total revenues reached $1.70 billion versus $1.03 billion in 2015. Net loss attributable to Vertex narrowed sharply to $112.1 million ($0.46 per share) from $556.3 million, and operating income turned positive at $9.9 million, the first annual operating profit cited in the filing's comparison period. The investment case rests on the pipeline and on ORKAMBI's ex-U.S. reimbursement path. Management expects to file an NDA for tezacaftor/ivacaftor in the second half of 2017 if Phase 3 data in the first half of 2017 are supportive, with triple-combination data from next-generation correctors (VX-152, VX-440) expected in the second half. Risk factors emphasize heavy dependence on CF revenues, with ORKAMBI and KALYDECO together accounting for nearly all revenue. KALYDECO was about 41% of 2016 revenues, and ORKAMBI's growth depends on European reimbursement timing, patient discontinuations, and a 2016 FDA complete response letter for ivacaftor in residual-function mutations. Balance sheet actions improved liquidity. Cash, equivalents and marketable securities rose to $1.43 billion. Vertex entered a $500 million revolving credit facility in October 2016, drew $300 million, and repaid it in February 2017. A subsequent January 2017 Merck KGaA deal brings a $230 million upfront payment for four oncology programs. Research and development expense of $1.05 billion remains very large relative to revenue, and the company has not yet reached sustained GAAP profitability.
Feb 23, 2017
2015
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2015
Vertex Pharmaceuticals' FY2015 10-K shows a company in transition from development to commercial-stage biotech, anchored by cystic fibrosis (CF). Total revenues rose 78% to $1.03 billion in 2015 from $580.4 million in 2014, driven by total net product revenues that more than doubled (up 105% to $1.0 billion). KALYDECO contributed $631.7 million and ORKAMBI, launched in the U.S. in the second half of 2015, contributed $350.7 million, with ORKAMBI revenue rising from $130.8 million in Q3 to $219.9 million in Q4. Despite this growth, the company posted a net loss attributable to Vertex of $556.3 million ($2.31 per share), an improvement from the $738.6 million loss in 2014, as R&D expense rose to $995.9 million and SG&A to $376.6 million. The investment case rests heavily on ORKAMBI's U.S. ramp and its ex-U.S. reimbursement timing. Management noted roughly 8,500 eligible U.S. patients, with more than 4,500 having started treatment by year-end, and said ex-U.S. ORKAMBI revenue will be concentrated in Germany until other European reimbursement discussions conclude. KALYDECO represented about 61% of 2015 revenue, down from 80% in 2014, and the FDA issued a Complete Response Letter in February 2016 on the sNDA for residual-function mutations, creating regulatory uncertainty. Pipeline spending is substantial, with a four-trial Phase 3 program for VX-661 and next-generation correctors, and the CRISPR and Parion collaborations added significant upfront payments. Balance sheet and liquidity are the key watch items. Cash, cash equivalents and marketable securities fell to $1.04 billion from $1.39 billion, and the company carries a $300 million senior secured term loan with $75 million quarterly principal repayments beginning October 2016, plus a covenant requiring minimum KALYDECO net revenues. Management states that cash flows and existing cash should fund operations for at least the next twelve months, but the company has a substantial accumulated deficit, a full valuation allowance on U.S. NOLs of about $4.2 billion, and a securities class action plus a DOJ subpoena still pending.
Feb 16, 2016
2014
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2014
Vertex Pharmaceuticals' FY2014 10-K shows a company in transition from a shrinking HCV franchise to a cystic fibrosis (CF) growth story. Total revenues fell 52% to $580.4 million in 2014 from $1.21 billion in 2013, as INCIVEK net product revenue collapsed to $24.1 million from $466.4 million. KALYDECO (ivacaftor) grew 25% to $463.8 million, now the company's core revenue driver, including $201.4 million from ex-U.S. markets. Net loss attributable to Vertex widened to $738.6 million ($3.14 per share) from $445.0 million in 2013, though 2013 included a $412.9 million VX-222 impairment, and 2014 included $50.9 million of restructuring charges tied to the Boston headquarters move and $45.2 million of net other expense driven largely by headquarters lease interest. The investment case rests almost entirely on lumacaftor in combination with ivacaftor for patients with two copies of the F508del mutation, roughly 22,000 patients across North America, Europe and Australia. The NDA was submitted in November 2014 with priority review, and the FDA PDUFA target date is July 5, 2015. The MAA is under Accelerated Assessment with EMA review expected in Q4 2015. Management expects U.S. revenue recognition to begin in mid-2015 and does not expect significant ex-U.S. revenue in 2015. The filing states that a significant portion of company value is tied to this combination, and that Vertex does not expect to be profitable in the near term. Liquidity is adequate but the balance sheet has become more leveraged. Cash, equivalents and marketable securities were $1.39 billion at year-end, down $78 million, after a $300 million Macquarie senior secured term loan (7.2% initial rate) drawn in July 2014, with amortization starting in October 2015. Management states cash flows from KALYDECO plus existing cash should fund operations for at least twelve months. The company also carries about $473 million of construction financing lease obligations tied to its Fan Pier headquarters, and a KALYDECO minimum-revenue covenant applies under the credit agreement. Investors should also weigh the pending securities class action (filed May 2014), dependence on a sole-source supplier, and a Massachusetts-based shareholder base that has seen significant share price volatility, from $59.79 to $124.35 during 2014.
Feb 13, 2015
2013
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2013
Vertex Pharmaceuticals' FY2013 10-K shows a company in transition away from its HCV franchise toward cystic fibrosis. Total revenues fell 21% to $1.21 billion, driven by a 37% drop in net product revenues to $837.6 million as INCIVEK sales collapsed after competing direct-acting antivirals were approved in late 2013. KALYDECO, the CF therapy, grew to $371.3 million, and management expects it to become the main revenue driver in 2014 even as total revenues are expected to decline significantly. The company reported a net loss attributable to Vertex of $445.0 million, or $1.98 per share, versus a $107.0 million loss in 2012. The result was driven by $663.5 million of intangible asset impairment charges on the HCV programs (VX-222 and VX-135), partly offset by a $152.0 million Janssen payment and a $68.2 million gain from deconsolidating Alios. Management guided to a substantial net loss in 2014 and a significant operating loss, and said it expects to sustain operations for at least twelve months from cash of about $1.47 billion. The key forward catalysts are the FDA's March 27, 2014 PDUFA date for the sNDA covering additional ivacaftor mutations, and mid-2014 Phase 3 data for the lumacaftor/ivacaftor combination in patients homozygous for F508del. The R117H Phase 3 trial missed its primary endpoint, and a shareholder class action remains pending. Investors should weigh the strength of the CF pipeline against the heavy near-term losses, the expiring HCV revenue base, and the regulatory and clinical binary events ahead.
Feb 11, 2014
2012
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2012
Vertex Pharmaceuticals' FY2012 10-K shows a company in transition from a single-blockbuster story to a two-product launch. Total revenues rose 8% to $1.53 billion (from $1.41 billion), driven by INCIVEK (telaprevir) net product revenues of $1.16 billion and first-year KALYDECO sales of $171.6 million, plus royalties on Janssen's INCIVO sales. However, the company posted a net loss attributable to Vertex of $(107.0) million, or $(0.50) per diluted share, versus net income of $29.6 million in 2011. The swing was driven by $133.2 million in inventory write-downs on excess INCIVEK, a $115.0 million increase in the fair value of contingent payments owed to Alios, and R&D and SG&A growth. Management explicitly guided that total revenues will decline in 2013 as INCIVEK sales erode, and INCIVEK quarterly revenue has been falling since its Q4 2011 peak (Q4 2012: $222.8 million). The investment case therefore rests on pipeline timing and KALYDECO expansion. Cash, cash equivalents and marketable securities were $1.3 billion at year-end, and management expects operating cash flow plus existing cash to fund operations for at least 12 months. Against that, the company carries $400 million of 3.35% convertible notes due October 2015 and has committed to roughly $1.0 billion of Fan Pier headquarters lease payments beginning December 2013. Key catalysts flagged include the initiation of a pivotal Phase 3 program for VX-809 with ivacaftor (data expected 2014), ivacaftor monotherapy Phase 3 label-expansion data in 2013, VX-509 Phase 2b data in 2H 2013, and VX-135-based all-oral regimens. Competitive risk is significant: Gilead's GS-7977 and Janssen's TMC435 are expected to reach the market as early as late 2013 or 2014, which management acknowledges could take a substantial share of HCV therapy. The filing also discloses a securities class action (City of Bristol Pension Fund) tied to May-June 2012 disclosures, which management believes is without merit, and a Massachusetts-law and sales-concentration profile in which two wholesalers (AmerisourceBergen and McKesson) account for over half of gross revenues. Net product revenue concentration in INCIVEK (87% of product revenues in 2012) is the central risk for investors.
Mar 1, 2013
2011
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2011
Vertex Pharmaceuticals' FY2011 10-K marks its transition from a development-stage biotech to a commercial company. Total revenues rose to $1.41 billion in 2011 from $143.4 million in 2010, driven by $950.9 million of net INCIVEK (telaprevir) product sales following the May 2011 U.S. launch, $409.7 million of collaborative revenues (including $318.5 million of milestones from Janssen and Mitsubishi Tanabe), and $50.0 million of royalties. The company reported net income attributable to Vertex of $29.6 million, or $0.14 per diluted share, versus losses of $754.6 million in 2010. Management says Vertex was cash-flow positive in the second half of 2011, with cash, cash equivalents and marketable securities of $968.9 million at year-end (excluding Alios cash). The 2011 result is flattered by one-time items. Collaborative milestone revenue of $318.5 million will not recur, since the company states it expects no further milestones from Janssen or Mitsubishi Tanabe, so collaborative revenues are guided to fall significantly in 2012. Earnings were also pressured by a $105.8 million impairment on VX-759, and by a $70.0 million increase in the fair value of contingent payments owed to Alios, the consolidated VIE. Operating expenses rose 54% to $1.30 billion, with SG&A up 113% to $400.7 million on the INCIVEK launch. Research and development spending increased 11% to $707.7 million. The investment case rests on whether INCIVEK can sustain sales against Merck's VICTRELIS and, later, all-oral interferon-free regimens expected around 2014-2015. Pipeline catalysts for 2012 include the first KALYDECO (ivacaftor) sales after its January 2012 FDA approval, a possible EU decision in the third quarter, interim ZENITH data from VX-222 combinations, and Phase 2 data for CF correctors. Risks include concentration in a single HCV product, a $400.0 million 3.35% convertible note due 2015, a $1.0 billion Fan Pier lease commitment, and a valuation allowance that keeps the company largely untaxed on its roughly $2.7 billion of federal NOLs.
Feb 22, 2012
2010
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2010
Vertex Pharmaceuticals' FY2010 10-K (filed February 17, 2011) is dominated by a single binary catalyst: telaprevir, its lead hepatitis C protease inhibitor. The NDA was submitted in November 2010 and granted priority review in January 2011, with an FDA target action date of May 23, 2011. Management expects a mid-2011 U.S. launch if approved, a Canadian launch in the second half of 2011, and an EU launch in the second half of 2011 by partner Janssen. The company is still pre-revenue on products. Its 2010 total revenues were $143.4 million (up 41%), driven mainly by collaborative revenues from Janssen and Mitsubishi Tanabe, while the net loss widened to $754.6 million ($3.77 per share) from $642.2 million. Most of the increase came from R&D (up 16% to $637.4 million, including a $65.9 million commercial supply investment) and SG&A (up 44% to $187.8 million) as the company builds a commercial organization. The balance sheet is strained but liquid. Cash, equivalents and marketable securities fell to $1.03 billion from $1.28 billion. Stockholders' equity dropped to $504 million from $1.10 billion, reflecting the accumulated deficit. Debt rose after the September 2010 issuance of $400 million of 3.35% convertible notes due 2015, and the 2012 secured notes ($155 million) are partly retired by Janssen milestone payments. Management says current resources fund operations for at least twelve months, and it expects cash-flow positivity in 2012 if telaprevir launches as planned. A January 2011 $100 million revolving credit facility carries a $400 million minimum cash covenant. Key investor considerations are the concentration of value in telaprevir, competition from Merck's boceprevir (which is under a similar FDA review timeline), reliance on Janssen and Mitsubishi Tanabe, and possible non-cash charges tied to the September 2009 financial transactions. Those charges could total $35.2 million more if the EU milestones are achieved. The VX-770 cystic fibrosis program, now in Phase 3, is the next major pipeline catalyst, with data expected in early 2011.
Feb 17, 2011
2009
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2009
Vertex Pharmaceuticals' FY2009 10-K shows a company in heavy investment mode ahead of a potential 2011 launch of its lead hepatitis C drug candidate, telaprevir. The company reported a net loss of $642.2 million ($3.71 per share) for 2009, up 40% from $459.9 million in 2008, as revenues fell 42% to $101.9 million on the absence of the large 2008 Janssen milestones. Management expects the 2010 net loss to exceed 2009's as it builds commercial supply and a sales force. Telaprevir's registration program (ADVANCE, ILLUMINATE, REALIZE) is fully enrolled, with SVR data expected in Q2 and Q3 2010, and an NDA planned for the second half of 2010. Telaprevir is the single most important value driver, and the filing states that a significant portion of investor valuation rests on it. Liquidity improved substantially. Cash, equivalents and marketable securities rose to $1.28 billion from $832 million, driven by roughly $801 million in net equity offerings, $155 million of secured 2012 Notes and $105 million from Mitsubishi Tanabe. Management states current resources should fund operations for at least twelve months, but these are financing-dependent and the company warns it may need to raise more capital if telaprevir is materially delayed. Note the $155 million 2012 Notes and the $95 million sale of future Janssen milestones, which together tie up roughly $250 million of expected EU milestone cash. The pipeline extends beyond HCV: VX-770 (CF, G551D mutation) is in Phase 3 with a possible NDA in 2H 2011, while VX-222 and VX-759 (acquired via ViroChem for $100 million cash plus stock) carry $518.7 million of in-process R&D intangibles, about 80% attributed to VX-222. Competitive risk is significant, since Merck's boceprevir could reach market on a similar timeline. The filing also flags a $7.2 million impairment on VCH-286 and the risk of larger future impairments on the ViroChem assets.
Feb 19, 2010
2008
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2008
Vertex Pharmaceuticals' 2008 10-K (filed February 17, 2009) describes a company whose value rests almost entirely on telaprevir, an oral hepatitis C protease inhibitor in Phase 3 development. The company remains pre-revenue on a product basis and reported a 2008 net loss of $459.9 million ($3.27 per share), up 18% from $391.3 million in 2007. Total revenues fell 12% to $175.5 million, driven by the May 2008 sale of its HIV royalty stream (Lexiva/Telzir) to Fosamprenavir Royalty for $160.0 million, and by lower CFFT collaboration revenue. Janssen supplied 68% of 2008 revenue, and the company expects Janssen-related revenue to decline in 2009 as milestone payments wind down. Financially, Vertex strengthened its balance sheet in 2008, ending the year with $832.1 million in cash, cash equivalents and marketable securities, up from $467.8 million, after a $391.3 million equity and convertible note raise in February, a $217.4 million equity offering in September, and the royalty sale. Offsetting this, the company took on $287.5 million of 4.75% convertible notes due 2013, and stockholders' equity fell to $238.9 million from $271.3 million as accumulated losses mounted. Management states that current resources, plus expected collaborator payments, should fund operations for at least twelve months, but it expects to need additional capital to complete telaprevir development and commercialization and has not provided a timeline for profitability. Key catalysts and risks lie ahead. The ADVANCE (treatment-naive) and REALIZE (treatment-experienced) Phase 3 trials completed enrollment in late 2008 and early 2009, with SVR data expected in the first half of 2010 and an NDA targeted for the second half of 2010. Competitor Schering-Plough's boceprevir could reach the market on a comparable timeline, and the company faces significant commercial-supply investment, a planned sales-force build, and leadership transition (Matthew Emmens becomes CEO in May 2009). Investors should weigh the binary nature of telaprevir's Phase 3 outcome against the company's substantial cash runway and ongoing collaboration support.
Feb 17, 2009
2007
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2007
Vertex Pharmaceuticals' FY2007 10-K shows a company in a heavy investment phase centered on its lead hepatitis C drug candidate, telaprevir. Net loss widened to $391.3 million ($3.03 per share) from $206.9 million in 2006, as R&D expense rose 38% to $513.1 million. Total revenue fell to $199.0 million from $216.4 million, with collaboration revenue (chiefly Janssen) of $151.0 million and Lexiva/Telzir royalties of $48.0 million. Management expects a significant operating loss in 2008 and continued losses beyond that. Liquidity is the central investor concern. Cash, cash equivalents and marketable securities fell $294.0 million to $467.8 million, and stockholders' equity dropped to $271.3 million from $505.9 million. Management says current resources fund operations through 2008, but the company expects to raise additional capital in 2008 to continue operations through 2009. All convertible debt was retired or converted during 2007, so the remaining financing risk is equity dilution or collaboration-based deals. The filing also notes about 132.9 million shares outstanding and roughly 15.4 million options at a $28.70 weighted-average exercise price. The key catalysts are telaprevir's Phase 3 program, which is expected to begin in March 2008 with SVR data from all arms in the first half of 2010, and the Phase 2b PROVE 1 and PROVE 2 interim results (61% and 68% SVR in 24-week arms). Investors should weigh these against the risks of trial outcomes, competing HCV protease inhibitors, rising commercial-supply spending, and a Kendall Square lease liability that management acknowledges may change materially.
Feb 11, 2008
2006
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2006
Vertex Pharmaceuticals' FY2006 10-K (filed March 1, 2007) describes a company transitioning from a collaboration-funded discovery model toward a fully integrated pharmaceutical company, with its lead asset telaprevir (VX-950, hepatitis C protease inhibitor) at the center of that shift. Vertex retained North American commercial rights to telaprevir under a June 2006 Janssen collaboration that provided a $165 million up-front payment and up to $380 million in contingent milestones, with Janssen covering 50% of development costs in its territories. The company is running three Phase 2b PROVE trials, expects to begin Phase 3 in the second half of 2007, and targets an NDA filing in late 2008 at the earliest. Management expects to invest heavily in 2007 (including $110-130 million in commercial supply investment for telaprevir), which will raise operating expenses materially. Financially, 2006 revenue rose 35% to $216.4 million, but the net loss widened to $206.9 million ($1.83 per share) as R&D expense climbed 50% to $371.7 million, partly driven by $32.0 million of stock-based compensation under FAS 123(R). Cash, cash equivalents and marketable securities increased to $761.8 million, supported by a $313.7 million September 2006 equity offering and the Janssen payment. Management states this is enough to fund operations for at least the next eighteen months. The company also redeemed its 5.75% 2011 convertible notes in March 2007, which should largely eliminate its convertible debt apart from $42.1 million of 2007 notes. Royalties from Lexiva/Telzir are growing but remain small relative to spending, and the company has no profitable product or visible path to profitability in the filing. Key risks for investors are concentrated: dependence on a single late-stage asset, Phase 2b data and regulatory timing, reliance on collaborators and third-party manufacturers, and a large Kendall Square lease liability with sublease-dependent estimates. The company explicitly warns that it expects operating losses to continue beyond 2007.
Mar 1, 2007
2005
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2005
Vertex Pharmaceuticals' FY2005 10-K shows a company still in heavy investment mode: net loss widened to $203.4 million ($2.28 per share) from $166.2 million in 2004, driven by R&D rising 29% to $248.5 million as the company advances VX-950 (hepatitis C), VX-702 (rheumatoid arthritis) and VX-770 (cystic fibrosis). Total revenue grew 57% to $160.9 million, supported by $32.8 million in Lexiva/Telzir royalties and $128.1 million in collaborative revenue, though roughly 61% of collaborative R&D revenue came from Novartis and Merck programs that conclude in April and June 2006. Management guided to a 2006 net loss of $205-225 million, revenue of $210-235 million and R&D of $350-370 million, and expects cash above $300 million at year-end 2006, which implies a reliance on new collaborations to replace expiring revenue. Balance sheet strength improved materially during 2005. A $165.4 million June equity offering and exchanges of roughly $155 million of convertible notes for about 10.6 million shares cut outstanding debt to about $160 million and lifted stockholders' equity from $35.4 million to $239.2 million. Cash, equivalents and marketable securities were $407.5 million at year-end. Management states this is sufficient for at least 18 months from filing, a horizon that frames the dilution and financing risk investors should weigh against the pipeline's binary clinical outcomes. The filing also flags several items that bear on the investment case. Pipeline progress was encouraging, with a 28-day Phase II VX-950 trial showing undetectable HCV RNA in all 12 patients, and a VX-702 Phase II RA trial meeting its primary ACR20 endpoint, though with modest effect sizes (40% vs. 30% placebo). Restructuring liabilities tied to the unused Kendall Square lease stand at $43.0 million, and FASB 123(R) adoption will add roughly $34 million of stock compensation expense in 2006. Concentration is high: Novartis, GlaxoSmithKline and Merck accounted for 33%, 33% and 15% of 2005 revenue.
Mar 16, 2006
2004
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2004
Vertex Pharmaceuticals' FY2004 10-K shows a company still deep in losses but actively restructuring its financing and collaboration model. Net loss narrowed to $166.2 million ($2.12 per share) from $196.8 million in 2003, driven by total revenue rising 49% to $102.7 million, mainly from new collaborations with Merck, Mitsubishi, and CFFT plus higher HIV royalties. Operating expenses remained heavy, with R&D of $192.2 million, and the 2003 restructuring charge ($91.8 million) was followed by a further $17.6 million charge tied to the unoccupied Kendall Square lease. The balance sheet is the key investor concern. Cash, cash equivalents and marketable securities fell to $392.3 million from $583.2 million, stockholders' equity dropped to $35.4 million from $192.8 million, and the company carries $315 million of convertible notes. Management deferred roughly 75% of its debt maturities from 2007 to 2011 through exchanges that lowered the conversion price on the new notes to $14.94, which increases dilution risk. Management guided to a 2005 net loss of $125-135 million before certain charges, revenue of $150-160 million, and R&D of $225-240 million, and said funds are sufficient for at least 18 months. The investment case rests on pipeline execution rather than current earnings. Near-term catalysts include merimepodib's METRO Phase IIb triple-combination study in hepatitis C, the VX-950 Phase Ib interim analysis, VX-765 psoriasis data, and the pralnacasan toxicology findings. Dependence on Novartis (49% of 2004 revenue) and GlaxoSmithKline (19%), the Kendall Square sublease outcome, and a pending securities class action (judgment for Vertex, appeal window through March 25, 2005) are additional risks.
Mar 16, 2005
2003-A
VERTEX PHARMACEUTICALS INC / MA Annual Report (Amendment), Year Ended Dec 31, 2003
Vertex Pharmaceuticals Inc. (VRTX) filed an amendment to its 2003 Form 10-K, primarily to provide additional disclosure on research and development expenses and the drug discovery process. The company, focused on small molecule drugs for serious diseases like HIV and hepatitis C, had two marketed products, Agenerase and Lexiva, through a collaboration with GlaxoSmithKline. The filing highlights a strategic shift towards prioritizing internal development of proprietary drug candidates, particularly in viral and inflammatory diseases, leading to a workforce reduction and a decision to not occupy a planned Kendall Square facility. This restructuring aimed to rebalance investment between research and development, with a notable increase in development spending and a decrease in research spending in 2003. Financials indicate continued operating losses, with a net loss of $196.8 million for 2003, but also significant cash reserves of $583.2 million at year-end 2003. Key financial guidance for 2004 includes an expected loss between $140-$150 million and total revenue between $90-$100 million. The company is actively seeking new collaborations to fund its discovery efforts beyond 2006 when its significant Novartis collaboration is set to conclude.
Sep 8, 2004
2003
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2003
Vertex Pharmaceuticals' FY2003 10-K shows a company in transition. Revenue fell to $69.1 million from $94.8 million in 2002, driven by the end of Lilly, Schering and Taisho funding and no new collaboration revenue since 2000. Net loss widened to $196.8 million, or $2.56 per share, from $108.6 million, mainly because of a $91.8 million restructuring charge tied to the Kendall Square lease. That charge was partly offset by a $69.6 million gain from discontinued operations after the sale of the Discovery Tools and Services business for about $101 million. R&D spending was roughly flat at $199.6 million. Novartis (64% of revenue) and GlaxoSmithKline (17%) account for most of the top line. The balance sheet is the key risk for investors. Cash and marketable securities were $583 million at year-end, but stockholders' equity fell to $192.8 million from $378.6 million. The company carries $315 million of 5% convertible notes due 2007. In February 2004 it exchanged $153.1 million of those for 5.75% notes due 2011, which pushed out much of the near-term repayment. The Kendall Square lease liability is $69.5 million, with total future lease obligations of up to $312.5 million, and the outcome depends on the sublease market. Management guides to a 2004 loss of $140-150 million and year-end 2004 cash above $350 million. It states that current funds are sufficient for at least 18 months. Pipeline progress is concentrated in viral and inflammatory disease. Lexiva was approved by the FDA in October 2003, and its EU approval is expected in 2004. Merimepodib (HCV) is in Phase II and VX-950 (HCV) is moving toward Phase I. VX-765 is in Phase I for inflammatory disease. Pralnacasan was voluntarily suspended over a liver fibrosis finding in nonclinical toxicology, with a 12-24 month delay possible. A shareholder class action relating to VX-745 is pending. The company remains unprofitable with no near-term path to profitability disclosed.
Mar 15, 2004
2002
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2002
Vertex Pharmaceuticals' 2002 Form 10-K reports a net loss of $108.6 million, or $1.43 per share, versus $66.2 million ($0.89 per share) in 2001. Total revenue was $161.1 million, down slightly from $167.5 million. Pharmaceutical revenue rose to $87.3 million, driven by Novartis kinase collaboration revenue of $41.9 million, while Discovery Tools and Services revenue fell 16% to $73.7 million as the company shifted away from instrumentation and sold PanVera assets. Research and development spending increased 35% to $203.0 million as Vertex advanced its own pipeline, which investors should weigh against the company's dependence on partner funding and royalties from Agenerase. The pipeline is the central investment story. GlaxoSmithKline filed an NDA for 908 (VX-175), an HIV protease inhibitor, in December 2002, with a U.S. launch targeted for Q4 2003. Vertex-driven candidates in Phase I or II include VX-148 (psoriasis), VX-702 (acute coronary syndromes), merimepodib (hepatitis C), and VX-563 (sickle cell disease). Management expects to select two priority candidates for internal U.S. development by year-end 2003. Partnered programs include pralnacasan with Aventis, which is in Phase II for rheumatoid arthritis and osteoarthritis. Balance sheet strength is a key positive. Cash and marketable securities were $635 million at year-end 2002, and the March 2003 sale of PanVera assets to Invitrogen for about $95 million is expected to produce a gain above $75 million. Against that, the company carries $315 million of 5% convertible notes due 2007, has an accumulated deficit of $423 million, and expects to remain loss-making in 2003, with a guided net loss of $140 to $160 million before the PanVera gain. The company also disclosed a Chiron patent suit and an Oregon Health Sciences University inventorship claim, and it is evaluating the Kendall Square lease obligation.
Mar 31, 2003
2001
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2001
Vertex Pharmaceuticals' 2001 10-K shows a company in heavy investment mode: total revenue rose to $167.5 million (from $139.0 million restated for 2000), but R&D spending climbed to $148.7 million and the company posted a net loss of $66.2 million, or $0.89 per share, after accounting charges. Vertex's revenue base remains concentrated: Agenerase (amprenavir) royalties were only $11.1 million in 2001 on $71.9 million of worldwide sales, and collaborative R&D revenue, led by the Novartis kinase deal, made up the largest revenue category at $69.0 million. Aurora Biosciences, acquired in July 2001 as a pooled transaction, added assay and screening services and product sales, and also contributed about $23.7 million in merger costs. The balance sheet is still strong, with $743.2 million in cash and marketable securities against $315 million of 5% convertible notes due 2007 and total stockholders' equity of $475.4 million. Management says current funds are sufficient for at least 18 months, though it guides to a significant operating loss in 2002 and to continuing losses beyond that. The pipeline has more than 12 candidates, with VX-175 (HIV, Phase III with GlaxoSmithKline) the most advanced of the clinical programs, and merimepodib (hepatitis C, Phase II) and pralnacasan (rheumatoid arthritis, Phase II with Aventis) next. Investors should weigh the approaching regulatory filing for VX-175, the dependence on partners such as Novartis and GlaxoSmithKline, and the ongoing Chiron and Oregon Health Sciences University patent suits. The filing also reports a change in revenue recognition (the Substantive Milestone Method), which produced a $25.9 million non-cash cumulative-effect charge and defers $35.2 million of revenue into later years. Pro forma net loss under the new method would have been $40.3 million, or $0.54 per share. The stock traded between $15.50 and $75.17 during 2001 and closed at $27.33 on March 26, 2002.
Apr 1, 2002
2000
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2000
Vertex Pharmaceuticals' FY2000 10-K shows a company in a major investment and expansion phase, funded heavily by new capital and partner payments rather than operations. Total revenues rose to $78.1 million in 2000 from $50.6 million in 1999, but the net loss widened to $39.7 million ($0.73 per share), including a $14.4 million make-whole charge on redeemed convertible notes and a $3.2 million non-cash cumulative effect charge from adopting SAB 101. Only $12.0 million of revenue came from royalties and product sales (Agenerase), while $66.1 million came from collaborative and R&D arrangements, so the company still depends on partner funding for much of its income. The balance sheet changed significantly. Cash and investments grew to $707.4 million after the issuance of $520 million in 5% convertible subordinated notes in March and September 2000, and about $170 million of the March notes converted into equity. Long-term debt is now $345 million in convertible notes, and management expects operating losses to continue beyond 2001 as research and development spending rises. Management states current funds are sufficient for at least 18 months. The pipeline is broad but early. Agenerase (amprenavir), marketed by GlaxoSmithKline, is the only approved product, with about 8% U.S. protease inhibitor share. Vertex has one Phase III candidate (VX-175), several Phase II programs (VX-497, VX-740 with Aventis, VX-745, Incel, timcodar), and a Novartis kinase collaboration worth up to roughly $600 million in pre-commercial payments. Key risks include dependence on partners, competition in HIV and RA markets, reliance on third-party manufacturing, a patent suit by Chiron, and high share price volatility, which ranged from $11.68 to $99.25 during 2000.
Mar 26, 2001
1999
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 1999
Vertex Pharmaceuticals' 10-K for fiscal 1999 shows a company in transition from discovery-stage biotech to early commercial operations. The first product, Agenerase (amprenavir), an HIV protease inhibitor, launched in May 1999 and generated $49.7 million in total sales over the last seven months of 1999, with Vertex receiving $7.5 million in royalties from Glaxo Wellcome. Total revenues rose 39% to $61.6 million from $44.4 million, but the net loss widened to $41.0 million ($1.61 per share) from $33.1 million, as R&D spending climbed to $72.2 million and SG&A to $26.1 million. Management guides to significant operating losses in 2000 and beyond, so profitability is not expected in the near term. The balance sheet remains solid but is shrinking. Cash and investments fell to $187.8 million from $245.7 million, driven by $31.8 million of operating cash burn and $16.2 million of capital spending. Management says existing resources should fund operations for at least two years, supplemented by Agenerase royalties, partner payments, and a new $20 million credit line. Partnership income is a significant part of the story: Aventis (VX-740, up to $62 million in milestones), Taisho (caspase inhibitors), Schering AG, Kissei, Eli Lilly, and Glaxo Wellcome all contribute research funding and milestone revenue. Key risks include a heavy reliance on partners for development and commercialization, limited marketing and manufacturing experience, competition from four other HIV protease inhibitors, an ongoing Chiron patent infringement suit, and the potential impact of SAB 101 revenue recognition rules on reported results in 2000. The stock traded between $19.38 and $82.56 over the prior twelve months, and the February 28, 2000 close was $62.00, reflecting investor enthusiasm about the pipeline and the chemogenomics platform.
Mar 3, 2000
1998
VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 1998
Vertex Pharmaceuticals' 1998 10-K describes a company still in the pre-revenue, clinical-stage phase, built around its structure-based drug design platform. Its lead product, Agenerase (amprenavir), an HIV protease inhibitor partnered with Glaxo Wellcome, had its New Drug Application filed in October 1998 under FDA fast-track designation, with review expected to conclude around mid-April 1999. Vertex has not yet received material product sales revenue. Upon approval, it expects royalty income on Glaxo Wellcome's sales, and it is also co-promoting the drug. Approval is not assured, and the filing notes that full approval depends on ongoing Phase III studies. Financially, 1998 total revenues were $44.4 million, roughly flat versus $43.8 million in 1997. Collaborative revenue fell slightly to $29.1 million, while investment income rose to $15.3 million. Research and development spending increased to $58.7 million and G&A rose sharply to $18.1 million, driven by headcount growth, legal costs for IP expansion, and pre-launch marketing. The net loss widened to $33.1 million ($1.31 per share) from $19.8 million ($0.82 per share). Cash and investments declined to $245.7 million from $279.7 million, and management expects continued losses in 1999 and possibly beyond, even if Agenerase royalties materialize. Cash burn was $31.1 million from operations, and the company expressed no concern about near-term funding. Investors should weigh the binary nature of the Agenerase regulatory decision against a broad but early pipeline. That pipeline includes Incel for multidrug resistance in cancer (Phase II), VX-497 for psoriasis and hepatitis C (Phase II), timcodar for diabetic neuropathy (Phase II), and VX-740 and VX-745 for inflammatory disease (Phase I). Key risks include dependence on collaborators, with Glaxo Wellcome able to terminate on 12 months' notice; a pending chiron patent infringement suit related to hepatitis C protease research; and the absence of internal manufacturing and sales capabilities.
Mar 30, 1999